- Home
- NUVL vs SNDR Comparison
NUVL vs SNDR Comparison
Compare NUVL & SNDR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- SNDR
- Stock Information
- Founded
- NUVL 2017
- SNDR 1935
- Country
- NUVL United States
- SNDR United States
- Employees
- NUVL N/A
- SNDR N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- SNDR Trucking Freight/Courier Services
- Sector
- NUVL Health Care
- SNDR Industrials
- Exchange
- NUVL Nasdaq
- SNDR Nasdaq
- Market Cap
- NUVL 4.9B
- SNDR 5.6B
- IPO Year
- NUVL 2021
- SNDR 2017
- Fundamental
- Price
- NUVL $87.24
- SNDR $30.17
- Analyst Decision
- NUVL Strong Buy
- SNDR Hold
- Analyst Count
- NUVL 10
- SNDR 14
- Target Price
- NUVL $112.60
- SNDR $27.77
- AVG Volume (30 Days)
- NUVL 492.9K
- SNDR 580.3K
- Earning Date
- NUVL 11-12-2024
- SNDR 11-06-2024
- Dividend Yield
- NUVL N/A
- SNDR 1.24%
- EPS Growth
- NUVL N/A
- SNDR N/A
- EPS
- NUVL N/A
- SNDR 0.64
- Revenue
- NUVL N/A
- SNDR $5,323,100,000.00
- Revenue This Year
- NUVL N/A
- SNDR N/A
- Revenue Next Year
- NUVL N/A
- SNDR $5.13
- P/E Ratio
- NUVL N/A
- SNDR $48.05
- Revenue Growth
- NUVL N/A
- SNDR N/A
- 52 Week Low
- NUVL $56.52
- SNDR $20.50
- 52 Week High
- NUVL $113.51
- SNDR $32.14
- Technical
- Relative Strength Index (RSI)
- NUVL 38.02
- SNDR 62.75
- Support Level
- NUVL $89.62
- SNDR $30.35
- Resistance Level
- NUVL $96.24
- SNDR $31.91
- Average True Range (ATR)
- NUVL 2.90
- SNDR 0.82
- MACD
- NUVL -0.27
- SNDR 0.14
- Stochastic Oscillator
- NUVL 15.96
- SNDR 62.95
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About SNDR Schneider National Inc.
Schneider National Inc is a provider of surface transportation and logistics solutions in North America. The Company offers truckload, intermodal, and logistics services to a diverse customer base throughout the continental United States, Canada, and Mexico. The company's segments include Truckload; Intermodal; Logistics and other. It generates maximum revenue from the Truckload segment.